company background image
URGN

UroGen Pharma NasdaqGM:URGN Stock Report

Last Price

US$8.05

Market Cap

US$183.1m

7D

-5.6%

1Y

-52.8%

Updated

27 Sep, 2022

Data

Company Financials +
URGN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

URGN Stock Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases.

UroGen Pharma Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for UroGen Pharma
Historical stock prices
Current Share PriceUS$8.05
52 Week HighUS$19.66
52 Week LowUS$4.85
Beta0.92
1 Month Change2.68%
3 Month Change3.07%
1 Year Change-52.84%
3 Year Change-65.88%
5 Year Change-74.82%
Change since IPO-42.42%

Recent News & Updates

Shareholder Returns

URGNUS BiotechsUS Market
7D-5.6%-3.3%-5.8%
1Y-52.8%-27.4%-22.1%

Return vs Industry: URGN underperformed the US Biotechs industry which returned -30.6% over the past year.

Return vs Market: URGN underperformed the US Market which returned -23.7% over the past year.

Price Volatility

Is URGN's price volatile compared to industry and market?
URGN volatility
URGN Average Weekly Movement8.4%
Biotechs Industry Average Movement11.0%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: URGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: URGN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004201Liz Barretthttps://www.urogen.com

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.

UroGen Pharma Ltd. Fundamentals Summary

How do UroGen Pharma's earnings and revenue compare to its market cap?
URGN fundamental statistics
Market CapUS$183.06m
Earnings (TTM)-US$113.75m
Revenue (TTM)US$57.69m

3.2x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
URGN income statement (TTM)
RevenueUS$57.69m
Cost of RevenueUS$6.20m
Gross ProfitUS$51.49m
Other ExpensesUS$165.24m
Earnings-US$113.75m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.00
Gross Margin89.25%
Net Profit Margin-197.16%
Debt/Equity Ratio-174.0%

How did URGN perform over the long term?

See historical performance and comparison